Clinical Trial Update: Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects [Phase 2]

View source ↗

Summary

ROSE-010, a GLP-1 analogue from Rose Pharma, completed a Phase 2 trial evaluating appetite effects in overweight and obese adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• ROSE-010 (glucagon-like peptide-1 analogue)

Snippet

Sponsor: Rose Pharma Inc | Conditions: Obesity; Overweight | Phase 2 | Status: COMPLETED